Abstract
Objective: The aim of this study was to investigate whether fibroblast growth factor receptor 4 (FGFR4) could serve as a potential therapeutic target, prognostic biomarker or biomarker predicting radiotherapy sensitivity in oral squamous cell carcinoma (OSCC) and oropharyngeal squamous cell carcinoma (OPSCC). Methods: FGFR4 immunohistochemistry and FGFR4/CEN5q FISH were performed on tissue microarrays from 212 OSCC and 238 OPSCC patients. FGFR4 genotypes were determined by PCR and DNA sequencing in 76 random OPSCC samples. The response to radiotherapy was evaluated 3 months after the last radiotherapy treatment session by a head and neck radiation oncologist and/or surgeon during clinic visits. The results were correlated to overall survival and response to radiotherapy. Results: The FGFR4 protein was overexpressed in 64% (153/238) of OPSCCs and 41% (87/212) of OSCCs. The FGFR4 gene was amplified in 0.47% (1/212) of OSCCs and 0.42% (1/238) of OPSCCs, and the FGFR4 Gly388Arg polymorphism was detected in 62% (47/76) of OPSCCs. FGFR4 protein expression, FGFR4 gene copy numbers and FGFR4 genotypes were not related to overall survival or response to radiotherapy in OSCC or OPSCC. Conclusion: FGFR4 is frequently overexpressed in OSCC and OPSCC in the absence of gene amplification, and may serve as a potential predictive marker for FGFR4-directed targeted therapy in OSCC and OPSCC.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 280-289 |
| Number of pages | 10 |
| Journal | Pathobiology |
| Volume | 82 |
| Issue number | 6 |
| DOIs | |
| State | Published - Nov 1 2015 |
| Externally published | Yes |
Fingerprint
Keywords
- Biomarker
- Fibroblast growth factor receptor 4
- Oral cancer
- Oropharyngeal cancer
- Therapeutic target
ASJC Scopus subject areas
- Pathology and Forensic Medicine
- Molecular Biology
- Cell Biology
Cite this
FGFR4 is a potential predictive biomarker in oral and oropharyngeal squamous cell carcinoma. / Koole, Koos; Van Kempen, Pauline M W; Van Bockel, Liselotte W.; Smets, Timo; Van Der Klooster, Zoë; Dutman, Annemiek C.; Peeters, Ton; Koole, Ron; Van Diest, Paul; Van Es, Robert J J; Willems, Stefan M.
In: Pathobiology, Vol. 82, No. 6, 01.11.2015, p. 280-289.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - FGFR4 is a potential predictive biomarker in oral and oropharyngeal squamous cell carcinoma
AU - Koole, Koos
AU - Van Kempen, Pauline M W
AU - Van Bockel, Liselotte W.
AU - Smets, Timo
AU - Van Der Klooster, Zoë
AU - Dutman, Annemiek C.
AU - Peeters, Ton
AU - Koole, Ron
AU - Van Diest, Paul
AU - Van Es, Robert J J
AU - Willems, Stefan M.
PY - 2015/11/1
Y1 - 2015/11/1
N2 - Objective: The aim of this study was to investigate whether fibroblast growth factor receptor 4 (FGFR4) could serve as a potential therapeutic target, prognostic biomarker or biomarker predicting radiotherapy sensitivity in oral squamous cell carcinoma (OSCC) and oropharyngeal squamous cell carcinoma (OPSCC). Methods: FGFR4 immunohistochemistry and FGFR4/CEN5q FISH were performed on tissue microarrays from 212 OSCC and 238 OPSCC patients. FGFR4 genotypes were determined by PCR and DNA sequencing in 76 random OPSCC samples. The response to radiotherapy was evaluated 3 months after the last radiotherapy treatment session by a head and neck radiation oncologist and/or surgeon during clinic visits. The results were correlated to overall survival and response to radiotherapy. Results: The FGFR4 protein was overexpressed in 64% (153/238) of OPSCCs and 41% (87/212) of OSCCs. The FGFR4 gene was amplified in 0.47% (1/212) of OSCCs and 0.42% (1/238) of OPSCCs, and the FGFR4 Gly388Arg polymorphism was detected in 62% (47/76) of OPSCCs. FGFR4 protein expression, FGFR4 gene copy numbers and FGFR4 genotypes were not related to overall survival or response to radiotherapy in OSCC or OPSCC. Conclusion: FGFR4 is frequently overexpressed in OSCC and OPSCC in the absence of gene amplification, and may serve as a potential predictive marker for FGFR4-directed targeted therapy in OSCC and OPSCC.
AB - Objective: The aim of this study was to investigate whether fibroblast growth factor receptor 4 (FGFR4) could serve as a potential therapeutic target, prognostic biomarker or biomarker predicting radiotherapy sensitivity in oral squamous cell carcinoma (OSCC) and oropharyngeal squamous cell carcinoma (OPSCC). Methods: FGFR4 immunohistochemistry and FGFR4/CEN5q FISH were performed on tissue microarrays from 212 OSCC and 238 OPSCC patients. FGFR4 genotypes were determined by PCR and DNA sequencing in 76 random OPSCC samples. The response to radiotherapy was evaluated 3 months after the last radiotherapy treatment session by a head and neck radiation oncologist and/or surgeon during clinic visits. The results were correlated to overall survival and response to radiotherapy. Results: The FGFR4 protein was overexpressed in 64% (153/238) of OPSCCs and 41% (87/212) of OSCCs. The FGFR4 gene was amplified in 0.47% (1/212) of OSCCs and 0.42% (1/238) of OPSCCs, and the FGFR4 Gly388Arg polymorphism was detected in 62% (47/76) of OPSCCs. FGFR4 protein expression, FGFR4 gene copy numbers and FGFR4 genotypes were not related to overall survival or response to radiotherapy in OSCC or OPSCC. Conclusion: FGFR4 is frequently overexpressed in OSCC and OPSCC in the absence of gene amplification, and may serve as a potential predictive marker for FGFR4-directed targeted therapy in OSCC and OPSCC.
KW - Biomarker
KW - Fibroblast growth factor receptor 4
KW - Oral cancer
KW - Oropharyngeal cancer
KW - Therapeutic target
UR - http://www.scopus.com/inward/record.url?scp=84946762384&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84946762384&partnerID=8YFLogxK
U2 - 10.1159/000439536
DO - 10.1159/000439536
M3 - Article
C2 - 26551585
AN - SCOPUS:84946762384
VL - 82
SP - 280
EP - 289
JO - Pathobiology
JF - Pathobiology
SN - 1015-2008
IS - 6
ER -